Real-World Evidence (RWE): Definition & Role in Pharma Medical Affairs

What are patient-reported outcomes?

Why PRO data matters in Medical Affairs and pharma

PRO data fills a gap that clinical endpoints alone can't: it captures what a treatment actually feels like to live with, which increasingly shapes regulatory, payer, and clinical conversations rather than sitting outside them. For Medical Affairs specifically, PRO data has become a legitimate input to real-world evidence generation and scientific exchange — not a soft metric owned solely by patient advocacy or commercial teams.

Regulators have formalized this shift. The FDA finalized its Core Patient-Reported Outcomes in Cancer Clinical Trials guidance in October 2024, building on its foundational 2009 guidance on using PRO instruments to support labeling claims, and followed with PFDD Guidance 3 on selecting and developing fit-for-purpose clinical outcome assessments in October 2025. The EMA has pursued parallel work on patient-centric evidence in benefit-risk assessment. When PRO methodology is this actively regulated, treating it as a checkbox rather than rigorous evidence is a missed opportunity — and a credibility risk.

PRO within the broader clinical outcome assessment (COA) framework

PRO is one of four recognized categories of clinical outcome assessment (COA), alongside clinician-reported outcomes (ClinRO), observer-reported outcomes (ObsRO), and performance outcomes (PerfO). What distinguishes PRO specifically is that the patient is the sole source — no clinician judgment sits between the patient's experience and the recorded data point. That distinction matters for regulatory submissions, where the FDA evaluates PRO instruments differently depending on whether they're intended to support an efficacy endpoint or a labeling claim.

How PRO data shows up in Medical Affairs work

• Real-world evidence generation: PRO data collected post-approval — often through digital or ePRO platforms — feeds RWE programs studying quality of life, treatment persistence, and symptom burden in real-world populations, distinct from the controlled conditions of a clinical trial.
• Scientific exchange: MSLs equipped with PRO data alongside clinical endpoints can have a fuller, more clinically grounded conversation with KOLs about what a treatment's benefit actually looks like for patients.
• HEOR and payer conversations: PRO data increasingly supports value dossiers and reimbursement discussions, particularly where a therapy's differentiation is more about symptom burden or function than a hard clinical endpoint.
• Patient advisory input: PRO data and qualitative patient advisory board input are complementary, not interchangeable — PRO carries the methodological rigor for regulatory and HEOR use; advisory input is better suited to shaping which questions get asked in the first place.

How TikaMobile helps

TikaMobile treats PRO-derived signal as evidence, not a side channel, routing it into the same insight infrastructure that captures every other real-world observation your team collects.

• PRO data alongside field insight: Patient-reported signal is tagged in the same evidence-gap taxonomy as MSL-captured field insights, so patterns across both data types are visible in one view.
• Traceable to scientific exchange: MSLs can surface relevant PRO context ahead of a KOL conversation instead of relying on memory or a separate HEOR report.
• Built for real-world evidence workflows: Structured capture supports the kind of longitudinal, real-world PRO tracking that feeds RWE study design.
• One system, not a parallel patient-insights database: No separate tool for patient-derived data that only one team ever opens.

Explore TikaMobile's Medical Insights platform →

Related: HEOR · Clinical Trial · Advisory Board (Pharma) · Payer